Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 03.03.20 in Vol 8, No 3 (2020): March

Preprints (earlier versions) of this paper are available at http://preprints.jmir.org/preprint/14130, first published Mar 25, 2019.

This paper is in the following e-collection/theme issue:

    Original Paper

    Use of an Electronic Clinical Decision Support System in Primary Care to Assess Inappropriate Polypharmacy in Young Seniors With Multimorbidity: Observational, Descriptive, Cross-Sectional Study

    1General Ricardos Primary Health Care Centre, Madrid, Spain

    2Medical Specialties and Public Health, School of Health Sciences, University Rey Juan Carlos, Alcorcón, Madrid, Spain

    3Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain

    4Research Support Unit, Primary Care Management, Madrid, Spain

    5Dirección Farmacia Atención Primaria Sector Zaragoza III, Zaragoza, Spain

    6Dirección Unidad Gestión Clínica Victoria en Málaga, Servicio Andaluz de Salud, Málaga, Spain

    7See Acknowledgments

    *all authors contributed equally

    Corresponding Author:

    Juan A Lopez-Rodriguez, MD, MSc, PhD

    General Ricardos Primary Health Care Centre

    Calle General Ricardos

    Madrid, 28019

    Spain

    Phone: 34 685197913

    Email: juanantonio.lopez@salud.madrid.org


    ABSTRACT

    Background: Multimorbidity is a global health problem that is usually associated with polypharmacy, which increases the risk of potentially inappropriate prescribing (PIP). PIP entails higher hospitalization rates and mortality and increased usage of services provided by the health system. Tools exist to improve prescription practices and decrease PIP, including screening tools and explicit criteria that can be applied in an automated manner.

    Objective: This study aimed to describe the prevalence of PIP in primary care consultations among patients aged 65-75 years with multimorbidity and polypharmacy, detected by an electronic clinical decision support system (ECDSS) following the 2015 American Geriatrics Society Beers Criteria, the European Screening Tool of Older Person’s Prescription (STOPP), and the Screening Tool to Alert doctors to Right Treatment (START).

    Methods: This was an observational, descriptive, cross-sectional study. The sample included 593 community-dwelling adults aged 65-75 years (henceforth called young seniors), with multimorbidity (≥3 diseases) and polypharmacy (≥5 medications), who had visited their primary care doctor at least once over the last year at 1 of the 38 health care centers participating in the Multimorbidity and Polypharmacy in Primary Care (Multi-PAP) trial. Sociodemographic data, clinical and pharmacological treatment variables, and PIP, as detected by 1 ECDSS, were recorded. A multivariate logistic regression model with robust estimators was built to assess the factors affecting PIP according to the STOPP criteria.

    Results: PIP was detected in 57.0% (338/593; 95% CI 53-61) and 72.8% (432/593; 95% CI 69.3-76.4) of the patients according to the STOPP criteria and the Beers Criteria, respectively, whereas 42.8% (254/593; 95% CI 38.9-46.8) of the patients partially met the START criteria. The most frequently detected PIPs were benzodiazepines (BZD) intake for more than 4 weeks (217/593, 36.6%) using the STOPP version 2 and the prolonged use of proton pump inhibitors (269/593, 45.4%) using the 2015 Beers Criteria. Being a woman (odds ratio [OR] 1.43, 95% CI 1.01-2.01; P=.04), taking a greater number of medicines (OR 1.25, 95% CI 1.14-1.37; P<.04), working in the primary sector (OR 1.91, 95% CI 1.25-2.93; P=.003), and being prescribed drugs for the central nervous system (OR 3.75, 95% CI 2.45-5.76; P<.001) were related to a higher frequency of PIP.

    Conclusions: There is a high prevalence of PIP in primary care as detected by an ECDSS in community-dwelling young seniors with comorbidity and polypharmacy. The specific PIP criteria defined by this study are consistent with the current literature. This ECDSS can be useful for supervising prescriptions in primary health care consultations.

    JMIR Med Inform 2020;8(3):e14130

    doi:10.2196/14130

    KEYWORDS



    Introduction

    Background

    Multimorbidity is defined by the World Health Organization as the coexistence of two or more chronic illnesses in a person [1]. It is a growing phenomenon that has become a health problem and an international health challenge [2] resulting from increased life expectancy and nontransmittable disease rates, among other factors. Patients with multimorbidity usually present with polypharmacy, defined as the simultaneous usage of several medicines. This definition is controverted, and there is no standard agreement on the number of drugs that indicates that the patient is polymedicated [3].

    Polypharmacy entails a greater risk for potentially inappropriate prescribing (PIP), which is defined as “the prescribing of medications or medication classes that should generally be avoided in persons 65 years or older because they are either ineffective or they pose unnecessarily high risk for older persons and a safer alternative is available (potentially inappropriate medication, PIM)” [4]. PIP also includes prescription omissions as the lack of use of potential right treatments. Data from the US National Health Survey yielded a prevalence of polypharmacy of 39% in the population aged older than 65 years [5]. A European study on medication dispensing for 310,000 adults within the UK National Health Service observed that the proportion of adult patients prescribed with 5 or more medicines doubled between 1995 and 2014, reaching 20.8% of the population [6]. For the same population age range in Spain, the percentage of polymedicated patients was approximately 50% [7]. The prevalence of patients with PIP is high, although it differs among studies, many of which are aimed at hospitalized, institutionalized, or immobilized elderly patients [8]. In the primary care setting in Europe, the PIP prevalence varies between 36% in Ireland [9] and 39% or 40.4% reported in 2 studies in Spain [10,11]. The existence of PIP has been related to a higher risk of being hospitalized [12], greater use of health emergency services and family doctor visits, reduced functionality [13], and increased mortality rates [14]. In terms of economic impact, some European studies estimate that the direct cost associated with PIP ranges between €188 and €318 (US $213-US $370) per patient per year [9,15].

    A number of tools have been developed for studying appropriate prescribing and facilitating the detection of PIP. There are implicit methods based on clinical judgment, such as the Medication Appropriateness Index [16], and explicit methods based on predefined criteria, such as the American Geriatrics Society Beers Criteria, the European Screening Tool of Older Person’s Prescribing (STOPP) Criteria, and the Screening Tool to Alert Doctors to the Right Treatment (START) Criteria. Although the Beers Criteria were the first to be published in 1991 [4] and have been the most widely employed to date, their application in the European setting is limited because they include a high percentage of pharmacological drugs not recognized in the majority of catalogs for European countries. To address this limitation, the criteria for the STOPP and START were set in 2008. Studies comparing the STOPP Criteria with other explicit criteria show that the STOPP Criteria are more exhaustive [9,15,17]. The STOPP, START, and Beers Criteria were updated and validated in Spanish in 2015 [18,19], but there are no studies comparing them.

    Some studies indicate that using the abovementioned tools to check prescribed medication translates into improved health outcomes for patients (falls, functionality, hospitalizations, number of consultations, and use of emergency services) [20]. However, applying these criteria requires extensive and updated clinical knowledge, time, and access to various simultaneous sources of information. For their use to be viable at primary care consultations, health professionals need automated, quick-to-consult tools that facilitate and supervise the process of medication prescribing. Electronic clinical decision support systems (ECDSSs) can improve prescription quality and reduce medication errors [21,22]. Although electronic clinical records are largely implemented in the Spanish primary care system, no adequate ECDSSs are currently available. Several clinical trials are being conducted to evaluate the use of ECDSSs in clinical practice [23-27].

    In Spain, an available ECDSS (CheckTheMeds Technology SL) has been used in the hospital setting and in pharmacological services offering a personalized system for medication dispensing [28,29]. This Web-based tool globally processes each patient’s information, combining clinical and pharmacological data, thus offering the health professional an analysis of criteria (Beers, STOPP, and START) for detecting PIP in real time.

    Objective

    The main aim of this study was to estimate the prevalence of PIP in young seniors (aged 65 to 75 years) with multimorbidity and polypharmacy, according to the updated criteria by the STOPP, START, and Beers, as detected by the ECDSS, at primary care consultations. The secondary objectives were to assess the relationships between clinical and sociodemographic variables and the presence of PIP.


    Methods

    Design

    This was an observational, cross-sectional, descriptive, multicentric study conducted in the Spanish primary care setting.

    Population

    This study included patients aged 65-75 years with multimorbidity (≥3 diseases) and polypharmacy (≥5 consumed medicines for at least 3 months), who had attended their doctor consultation at least once over the last year and provided written consent to participate in the Multimorbidity and Polypharmacy in Primary Care (Multi-PAP) trial [30]. Institutionalized patients—those whose life expectancy was less than 12 months, as estimated by their doctor—and patients with any severe mental disorder were excluded. Recruitment physicians did not receive any economic incentives. Each doctor offered participation to patients from a random list of patients potentially meeting the inclusion criteria. A total of 117 family doctors from 38 health care centers from 3 Spanish regions (Andalucia, Aragon, and Madrid) included a total of 593 subjects who agreed to participate. On the basis of the previous studies reporting a PIP percentage of 39% [10], with this sample size, a maximum type 1 error of 3.9% with a 95% CI was reported.

    Variables

    The following sociodemographic variables were recorded for patients: age, gender, marital status, educational level, social class according to the Spanish classification [31], and family income in thousands of euros adjusted by the number of people in the household using the method proposed by the Organisation for Economic Cooperation and Development. In addition, the following clinical variables were collected: number of active pharmaceutical ingredients per patient according to the Anatomical Therapeutic Chemical (ATC) classification system and chronic conditions in accordance with the International Classification of Primary Care, with the most relevant ones selected according to the criterion by O’Halloran et al [32]. The assessed PIP variables were existence of STOPP and START criteria following its Spanish-adapted 2014 version [18], existence of Beers 2015 version criteria [19], number of STOPP criteria, number of START criteria, number of Beers Criteria, and classification of the type of detected criteria.

    Sociodemographic and clinical data were obtained between December 2016 and January 2017 through an interview by each patient’s doctor and recorded in a data collection notebook (DCN). Subsequently, in April 2018, the data were uploaded from the DCN into the ECDSS. One researcher with vast clinical and therapeutic drug monitoring experience supervised the information transfer to the CheckTheMeds Technology SL and used this tool to globally review the treatment of all patients. The latest versions of the STOPP, START, and Beers Criteria were employed.

    All the STOPP and Beers Criteria were analyzed. In agreement with previous studies [33] and to avoid potential information bias, this research team agreed on omitting the A1 STOPP criterion from the analysis (any drug prescribed but not indicated by clinical evidence) to prevent its overestimation [33].

    Statistical Analysis

    Categorical variables were described by their frequencies and percentages. Quantitative variables were described by their mean and SD, with their corresponding 95% CI when they fit a normal distribution, or by their median and IQR in the case of asymmetric distributions. The presence of one or more PIP was identified, and the association between groups was assessed for the main variables using a chi-square test in the case of categorical variables or the Student t test (Mann-Whitney U test when the variable did not fit a normal distribution) in the case of quantitative ones. A multivariate logistic regression model was built to study factors related to PIP, with robust estimators that controlled for the effect of cluster sampling. The dependent variable was the presence of one or more PIP according to the STOPP version 2 (V2) criteria, and independent variables were those reaching statistical significance in the bivariate analysis or considered of clinical relevance. Stata version 14.0 (StataCorp LLC) and IBM SPSS 21 software (IBM Corp) were employed in the statistical analyses.


    Results

    A total of 4386 prescriptions were recorded for the 593 included patients (593/635, 93.4% of the total offered for participation). The average age of patients was 69.7 (SD 2.7) years; 56.3% (334/593) of the patients were women, 75.4% (447/593) were married, and 17.9% (106/593) lived by themselves. Multimedia Appendix 1 describes the main sociodemographic and clinical characteristics for each group according to the presence or absence of PIP or medication omissions according to the START Criteria. The most frequent pathologies were high blood pressure that amounted to 78.9% cases (468/593) and hypercholesterolemia with 50.2% cases (301/593). Of the 593 patients, 250 (42.2%) were diabetic, 215 (36.3%) had arthritis (knee, hip, or other joints), and 220 (37.1%) had mental disorders (for a complete list of disease prevalence, see Multimedia Appendix 2). The median number of chronic illnesses per patient was 5 (IQR 4-7). The median number of medicines per patient was 7 (IQR 6-9), and 17.9% (106/593) of the patients were prescribed ≥10 drugs. In terms of ATC groups, the cardiovascular one was the most frequent, with 95.3% (565/593) subjects taking at least one drug, followed by the digestive system/metabolism and the nervous system groups. The most prescribed drug was omeprazole, which was taken by 49.2% (292/593) of patients, followed by acetylsalicylic acid by 36.8% (218/593) of patients, metformin by 34.4% (204/593) of patients, simvastatin by 32.9% (195/593) of patients, and enalapril by 27.2% (161/593) of patients.

    The frequency for the ECDSS to detect at least one explicit criterion was 57.0% (95% CI 53-61), 42.8% (95% CI 38.9-46.8), and 72.8% (95% CI 69.3-76.4) applying the STOPP, START, and Beers Criteria, respectively, all in their latest versions at the point when this study was conducted (Table 1). The percentage of patients that met three or more Beers Criteria was 16.5% (98/593). Of the overall criteria evaluated for the studied sample, 30 different criteria were detected in the STOPP, 21 in the START, and 34 in the Beers Criteria (see Multimedia Appendix 3). The most frequently found PIP according to the STOPP criteria were the prolonged use of benzodiazepines (BZD) in 36.6% of patients (217/593), followed by beta blockers in 12.5% (74/593) of patients with diabetes mellitus with frequent episodes of hypoglycemia and the prescribed use of opioids without associated laxatives found in 5.4% (32/593) of patients. Following the Beers Criteria, the most frequent PIP were the prolonged use of proton pump inhibitors (PPIs) by 45.4% (269/593) of patients, prolonged use of BZD and hypnotic drugs by 27% (160/593) of patients, and prolonged use of antidepressants or the combined use of 2 or more central nervous system depressants by 17.4% (130/593) of patients (Multimedia Appendix 2).

    At least one PIP was detected using both methods in 40.8% (242/593) of patients, and disagreement was found in 32.0% (190/593) of patients for whom 1 PIP was detected according to the Beers Criteria but did not meet any criterion in the STOPP. On the contrary, 16.2% (96/593) of patients presented with some PIP using the STOPP criteria, but none using the Beers Criteria.

    Factors that were found to relate to the presence of PIP were being a woman, greater medicine intake, belonging to social class 2 (qualified primary sector), and using a pharmacological treatment for the central nervous system (Anatomical Therapeutic Chemical classification system-nervous system [ATC-N]; see Table 2).

    The most frequent omission of medicines detected by the START criteria in 593 patients were inhaled corticosteroids in 55 (9.3%) patients with asthma or severe chronic obstructive pulmonary disease (COPD); prostaglandins, prostamide, or topical beta blockers in 40 (6.7%) patients with primary open-angle glaucoma; calcium and vitamin D supplements in 37 (6.2%) patients with osteoporosis; and inhibitors of 5α-reductase also in 37 (6.2%) patients for the treatment of symptomatic prostatism when prostatectomy is not necessary (see Multimedia Appendix 2).

    Table 1. Percentage of detected potentially inappropriate prescribing (potentially inappropriate medication or prescription omission) according to the different criteria sets.
    View this table
    Table 2. Factors associated with a potentially inappropriate medication according to the Screening Tool of Older Person’s Prescription criteria.
    View this table

    Discussion

    Principal Findings

    The percentage of patients in the sample with one or more PIP was 57.0% (338/593) using STOPP (95% CI 53-61), 72.8% (432/593) with Beers (95% CI 69.3-76.4), and 42.8% (254/593) with START (95% CI 38.9-46.8). The most frequent PIPs were the use of BZD for more than 4 weeks according to the STOPP V2 criteria (217/593, 36.6%) and the prolonged use of PPI using the Beers 2015 version (269/593, 45.4%). Factors associated with a higher PIP frequency were being a woman (OR 1.43, 95% CI 1.01-2.01; P=.04), greater medicine intake (OR 1.25, 95% CI 1.14-1.37; P<.001), being a primary sector worker (OR 1.91, 95% CI 1.25-2.93; P=.003), and using pharmacological treatments for the central nervous system (OR 3.75, 95% CI 2.45-5.76; P<.001). Both the STOPP and Beers tools simultaneously detected one or more PIP in 40.8% (242/593) of the patients. Differences were found using the STOPP and Beers sets of criteria, and the difficulties for using some of the explicit criteria were found by the ECDSS.

    Prevalence of Potentially Inappropriate Prescribing

    The prevalence of PIP among community-dwelling young seniors varies depending on the explicit criteria employed as well as the different study designs and included populations [15,18,34]. This study obtained a prevalence of 57.0% in accordance with the STOPP criteria, which is higher than that of previous studies [9,10] using previous STOPP versions in the primary care setting and the European population (36% and 39%, respectively). Studies using the STOPP 2014 version found prevalence values of 8.7% and 40.4% [11,33]. The study by Blanco-Reina et al [11], with similar data to ours, obtained a prevalence of 40.4% in contrast to the 18.7% obtained using the original STOPP version and concluded that the latest version is more sensitive for PIP detection. The greater prevalence observed in this study can result from the included population, which had to meet the polypharmacy criterion to participate in the Multi-PAP trial group, whereas only 72.9% of the patients in the abovementioned study were polymedicated.

    Following the Beers 2015 version criteria, the PIP prevalence (77.2%) was higher than that described in some previous studies. Owing to the repeated updates of these criteria (5 up to 2015) and different study designs and studied populations, there is great variability in the obtained prevalence values [34]. Studies using the Beers 2015 version reported a prevalence ranging from 53.5% in the hospitalized population [35] to 72.8% in studies based on big data [36]. In Spain, using the 2008 and 2012 versions, the prevalence of PIP varied from 24.3% to 44.0%, respectively [37].

    Studies comparing the 2015 version with the 2012 versions of Beers Criteria [35] confirmed that the latest version has greater sensitivity for detecting PIP. The increased number of criteria in the Beers 2015 version and the adaptation of the medications catalog [17], together with the application of these criteria to a polymedicated population, can explain the higher prevalence found in our sample.

    The percentage of patients with one or more medication omission was 42.8%, a figure superior to those in previous studies, where it ranged between 22.0% and 39.9% using the START criteria [10,11,33,37].

    Most Frequent Screening Tool of Older Person’s Prescription and Screening Tool to Alert Doctors to Right Treatment, the Beers Criteria

    In agreement with most previous studies, BZD and PPI were the most frequent PIP detected [10,11,15,33,37]. The proportion of patients using BZD for more than 4 weeks in the studied sample using STOPP V2 is similar to that found by Blanco-Reina et al [11] (36.6% vs 38.6%, respectively), whereas the use of BZD and hypnotic drugs using the Beers Criteria was lower than that observed in the mentioned study (26.9% vs 52.4%, respectively) but similar to that in a study by Zhang et al (29.8%) [35]. The reason for this difference can be that the most used BZD by patients in this study were lorazepam (13.5%), bromazepam (8.6%), and lormetazepam (6.9%), with the 2 latest being included in the catalog of medicines detected by the STOPP criteria but not in the catalog for the Beers. The work by Blanco-Reina et al [11], which did not specify what the most used BZD were, reported that 46.7% of patients had insomnia, a figure much higher than the one observed in our sample, which could explain the differences between them.

    This study found that the prolonged use of PPI was the most frequent PIP detected by the Beers latest version (45.5%), although it was not detected using STOPP. Several systematic reviews report it as one of the most frequent PIP observed in the polymedicated population in accordance with different explicit criteria [15,34,38]. The Beers 2015 updated version included this criterion that is already described as frequent (41.9%) by some authors [35], although their samples are not comparable with ours. Some studies that identified this PIP as frequent [9,10] employed a modified version of STOPP that facilitates its detection, instead of the original criterion that is associated with a specific clinical condition that limits its capacity for such purpose (PPI for treating peptic ulcer disease without complications or peptic erosive esophagitis with full therapeutic doses for more than 8 weeks). For example, 40 mg of omeprazole was considered the full therapeutic dose by the ECDSS.

    The use of nonsteroidal anti-inflammatory drugs (NSAIDs) also appears in the current literature as one the most frequently found PIP in the polymedicated population [15,34,38]. This criterion only was met by 1.5% of patients in the study by Blanco-Reina et al [11], which used a similar methodology to ours. As their own family doctors were the ones entering the pharmacological information for their patients in the DCN, a bias can be present in the outcome if the patient was taking the NSAIDs, but the doctor did not consider it as their regular chronic medication and hence did not include it in the DCN. This record omission, together with the ample information on increased cardiovascular risk associated with these drugs, can explain the observed differences.

    In studies using the START 2014, the most relevant omission criterion is the use of inhaled corticosteroids in patients with asthma or severe COPD as well as the use of calcium and vitamin D supplements in patients with osteoporosis, as was the case in our sample. The criterion for prostaglandin, prostamides, or topical beta blockers in patients with primary open-angle glaucoma can be overestimated because topical medication was not recorded, which can partially explain the high prevalence of omissions in this trial.

    Factors relating to the presence of PIP as detected using the STOPP are similar to those in previous studies [15,34] that have identified a relationship between being a woman and taking a greater number of medicines with the presence of PIP. These studies also found a correlation with poor economic status, which was not the case in our study, although the classification systems for the economic level and social class are not comparable. The ATC-N includes all the drugs in the BZD group as well as antidepressants, thus its association with the presence of PIP.

    Agreement Between Methods

    Only 40.0% (237/593) of patients were simultaneously detected with one or more PIP according to the criteria of the Beers and STOPP methods. The use of different medication catalogs by these tools does not entirely explain the observed discrepancies. Although previous studies have analyzed the agreement between both the tools in terms of the overall percentage of detected PIP [11,37,39], they did not take into consideration that the drugs and clinical scenarios assessed by each method are different and changed throughout their updated versions. In a review by Motter et al [17], a detailed analysis of differences among the existing explicit criteria since 1991 (STOPP, Beers, and others) was conducted; they concluded that these tools assess different parameters, medicines, and clinical scenarios, which are not readily comparable. Given the differences between these tools, their combined use in a complementary manner is probably the most adequate approach.

    Algorithms Used by the Electronic Clinical Decision Support System

    ECDSSs are very helpful tools for applying different explicit criteria simultaneously [40,41]. Translating the STOPP criteria into computerized algorithms to be used by an ECDSS can be more complicated than doing so for the Beers Criteria. This was evident in our study in terms of the difficulty found in detecting the usage of PPIs for more than 8 weeks using the STOPP criteria, as previously mentioned. The majority of the STOPP criteria are linked to a clinical condition that is often difficult to codify or extract from the patient’s electronic clinical records [42]. Studies evaluating an ECDSS [43] that applies the explicit criteria in the latest versions of these tools estimate that 67% of the STOPP criteria require additional clinical information vs 31% for Beers. Many studies employ several criteria instead of the complete list; hence, the analysis of prescriptions remains incomplete [44], whereas others [10] use free adaptations of the criteria to facilitate the development of computerized algorithms.

    Strengths and Limitations

    Not exporting the data directly from clinical records but from a DCN designed ad hoc could have potentially introduced an information bias regarding illnesses and pharmacological treatment. Given the design of the Multi-PAP trial, health professionals may have prioritized pathologies they considered chronic and were included in the classification employed in the trial instead of registering the total number of patients’ diseases. Something similar may have occurred with topical medication as the research team decided not to include it in the study because it is not associated with significant adverse effects. This bias could have resulted in an overestimation of the prevalence of certain STOPP or START criteria that the research team tried to correct by adjusting the A1P criterion.

    The pragmatic design of the study is among our strengths, with patients comprising a representative sample of the community-dwelling young seniors with multimorbidity and polypharmacy, who were interviewed and evaluated by their usual doctors during clinical practice. Overall, this age group has a good quality of life and substantial potential for early interventions.

    Applicability of the Outcome

    Using the ECDSS allows for a rapid, complete, and simultaneous evaluation of PIP based on different explicit criteria. This tool can support family doctors when deciding what the best therapeutic choice is for each patient, not only to review the therapeutic plan but also to prescribe new treatments. In any event, even after the information is provided via the ECDSS, the professional must always evaluate it and make the final decision. The decision to continue or discontinue certain treatments must be made based on clinical conditions and within a framework of a doctor-patient shared decision making. The evaluation of this tool in the future in clinical effectiveness and implementation of hybrid design studies will help in integrating them into the clinical electronic records of patients.

    Acknowledgments

    This study was financed by the Fondo de Investigaciones Sanitarias Coordinated project (grant references PI15/00276, PI15/00572, PI15/00996) from the Instituto de Salud Carlos III.

    Andalusia MultiPAP Group: Juan Daniel Prados Torres, Francisca Leiva Fernández, José María Ruiz-San-Basilio, Ana M López-León, Carmina Mateos-Sancho, Nuria García-Agua, Rubén Vázquez-Alarcón, Maria Isabel Márquez-Chamizo, and Mercedes Clerencia-Sierra; Aragon MultiPAP Group: Alexandra Prados Torres, Mercedes Aza-Pascual-Salcedo, Antonio Poncel-Falcó, Antonio Gimeno-Miguel, Ana Cristina Bandrés-Liso, Javier Marta-Moreno, and José María Abad-Díez; and Madrid MultiPAP Group: Marta Alcaraz-Borrajo: Ángel Mataix-San-Juan, Virginia Hernández-Santiago, Ricardo Rodríguez-Barrientos, Luis Sánchez-Perruca, Elena Polentinos-Castro, Gloria Ariza-Cardiel, Ana Isabel González-González, Milagros Rico-Blázquez, M Eugenia Tello-Bernabé, Mercedes Rumayor-Zarzuelo.

    Participating primary care health centers and family physicians in Argon are as follows: PCHC Alcorisa (Alcorisa): Carmen Sánchez Celaya del Pozo; PCHC Delicias Norte (Zaragoza): José Ignacio Torrente Garrido, Concepción García Aranda, Marina Pinilla Lafuente, and M Teresa Delgado Marroquín; PCHC Picarral (Zaragoza): M José Gracia Molina, Javier Cuartero Bernal, M Victoria Asín Martín, and Susana García Domínguez; PCHC Fuentes de Ebro (Zaragoza): Carlos Bolea Gorbea; PCHC Valdefierro (Zaragoza): Antonio Luis Oto Negre; PCHC Actur Norte (Zaragoza): Eugenio Galve Royo and M Begoña Abadía Taira; PCHC Alcañiz (Alcañiz): José Fernando Tomás Gutiérrez; PCHC Sagasta - Ruiseñores (Zaragoza): José Porta Quintana, Valentina Martín Miguel, Esther Mateo de las Heras, and Carmen Esteban Algora; PCHC Ejea (Ejea de los Caballeros): M Teresa Martín Nasarre de Letosa, Elena Gascón del Prim, Noelia Sorinas Delgado, and M Rosario Sanjuan Cortés; PCHC Canal Imperial-Venecia (Zaragoza): Teodoro Corrales Sánchez; PCHC Canal Imperial-San José Sur (Zaragoza): Eustaquio Dendarieta Lucas; PCHC Jaca (Jaca): M del Pilar Mínguez Sorio and Virginia López Cortés; and PCHC Santo Grial (Huesca): Adolfo Cajal Marzal.

    Participating primary health care centers and family physicians in Madrid are as follows: PCHC Mendiguchía Carriche (Leganés): Eduardo Díaz García, Juan Carlos García Álvarez, Francisca García De Blas González, Cristina Guisado Pérez, Alberto López García Franco, and M Elisa Viñuela Beneitez; PCHC El Greco (Getafe): Ana Ballarín González, M Isabel Ferrer Zapata, Esther Gómez Suarez, Fernanda Morales Ortiz, Lourdes Carolina Peláez Laguno, José Luis Quintana Gómez, and Enrique Revilla Pascual; PCHC Cuzco (Fuenlabrada): M Ángeles Miguel Abanto; PCHC El Soto (Móstoles): Blanca Gutiérrez Teira; PCHC General Ricardos (Madrid): Francisco Ramón Abellán López, Carlos Casado Álvaro, Paulino Cubero González, Santiago Manuel Machín Hamalainen, Raquel Mateo Fernández, M Eloisa Rogero Blanco, and Cesar Sánchez Arce; PCHC Ibiza (Madrid): Jorge Olmedo Galindo; PCHC Las Américas (Parla): Claudia López Marcos, Soledad Lorenzo Borda, Juan Carlos Moreno Fernández, Belén Muñoz Gómez, and Enrique Rodríguez De Mingo; PCHC M Ángeles López (Leganés): Juan Pedro Calvo Pascual, Margarita Gómez Barroso, Beatriz López Serrano, M Paloma Morso Peláez, Julio Sánchez Salvador, Jeannet Dolores Sánchez Yépez, and Ana Sosa Alonso; PCHC M Jesús Hereza (Leganés): M del Mar Álvarez Villalba; PCHC Pavones (Madrid): Purificación Magán Tapia; PCHC Pedro Laín Entralgo (Alcorcón): M Angelica Fajardo Alcántara, M Canto De Hoyos Alonso, and M Aránzazu Murciano Antón; PCHC Pintores (Parla): Manuel Antonio Alonso Pérez, Amaya Azcoaga Lorenzo, Ricardo De Felipe Medina, Amaya Nuria López Laguna, Eva Martínez Cid De Rivera, Iliana Serrano Flores, and M Jesús Sousa Rodríguez; and PCHC Ramón y Cajal (Alcorcón): M Soledad Núñez Isabel, Jesús M Redondo Sánchez, Pedro Sánchez Llanos, and Lourdes Visedo Campillo.

    Participating primary health care and family physicians in Andalusia are as follows: PCHC Alhaurín el Grande: Javier Martín Izquierdo and Macarena Toro Sainz; PCHC Carranque: M José Fernández Jiménez, Esperanza Mora García, and José Manuel Navarro Jiménez; PCHC Ciudad Jardín: Deborah Gil Gómez, Leovigildo Ginel Mendoza, and Luz Pilar de la Mota Ybancos, Jaime Sasporte Genafo; PCHC Coín: M José Alcaide Rodríguez, Elena Barceló Garach, Beatriz Caffarena de Arteaga, M Dolores Gallego Parrilla, and Catalina Sánchez Morales; PCHC Delicias: M del Mar Loubet Chasco, Irene Martínez Ríos, and Elena Mateo Delgado; PCHC La Roca: Esther Martín Aurioles; PCHC Limonar: Sylvia Hazañas Ruiz; PCHC Palmilla: Nieves Muñoz Escalante; PCHC Puerta Blanca: Enrique Leonés Salido, M Antonia Máximo Torres, M Luisa Moya Rodríguez, Encarnación Peláez Gálvez, José Manuel Ramírez Torres, and Cristóbal Trillo Fernández; PCHC Tiro Pichón: M Dolores García Martínez Cañavate, M del Mar Gil Mellado, and M Victoria Muñoz Pradilla; PCHC Vélez Sur: M José Clavijo Peña, José Leiva Fernández, and Virginia Castillo Romero; and PCHC Victoria: Rafael Ángel Maqueda, Gloria Aycart Valdés, Miguel Domínguez Santaella, Ana M Fernández Vargas, Irene García, Antonia González Rodríguez, M Carmen Molina Mendaño, Juana Morales Naranjo, Catalina Moreno Torres, and Francisco Serrano Guerra.

    Conflicts of Interest

    None declared.

    Multimedia Appendix 1

    Sociodemographic, clinical, and pharmacological characteristics of patients.

    XLSX File (Microsoft Excel File), 16 KB

    Multimedia Appendix 2

    Disease List Prevalence according to International Classification in Primary Care.

    XLSX File (Microsoft Excel File), 14 KB

    Multimedia Appendix 3

    List of all screening tool of older people's prescriptions, screening tool to alert to right treatment, and Beers criteria.

    XLSX File (Microsoft Excel File), 16 KB

    References

    1. World Health Organization. 2008. The World Health Report 2008 - primary Health Care (Now More Than Ever)   URL: https://www.who.int/whr/2008/en/
    2. The Academy of Medical Sciences. 2018 Apr. Multimorbidity: a priority for global health research   URL: https://acmedsci.ac.uk/file-download/82222577
    3. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2018 Dec 03;9:CD008165. [CrossRef] [Medline]
    4. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991 Sep;151(9):1825-1832. [Medline]
    5. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. J Am Med Assoc 2015 Nov 03;314(17):1818-1831 [FREE Full text] [CrossRef] [Medline]
    6. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med 2015 Apr 07;13:74 [FREE Full text] [CrossRef] [Medline]
    7. Molina López T, Caraballo Camacho MD, Palma Morgado D, López Rubio S, Domínguez Camacho JC, Morales Serna JC. [Prevalence of multiple medication and cardiovascular risk in patients over 65 years]. Aten Primaria 2012 Apr;44(4):216-222 [FREE Full text] [CrossRef] [Medline]
    8. Gavilán Moral E, Morales Suárez-Varela MT, Hoyos Esteban JA, Pérez Suanes AM. Polimedicación y prescripción de fármacos inadecuados en pacientes ancianos inmovilizados que viven en la comunidad. Atención Primaria 2006 Nov;38(9):476-480. [CrossRef]
    9. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010 May;69(5):543-552 [FREE Full text] [CrossRef] [Medline]
    10. Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galván-Santiago L, Serrano-Godoy M, Ribes-Murillo E, en representación del grupo de investigación GRETAP. [Potentially inappropriate prescribing in older Spanish population according to STOPP/START criteria (STARTREC study)]. Aten Primaria 2017 Mar;49(3):166-176 [FREE Full text] [CrossRef] [Medline]
    11. Blanco-Reina E, García-Merino MR, Ocaña-Riola R, Aguilar-Cano L, Valdellós J, Bellido-Estévez I, et al. Assessing potentially inappropriate prescribing in community-dwelling older patients using the updated version of STOPP-START criteria: a comparison of profiles and prevalences with respect to the original version. PLoS One 2016;11(12):e0167586 [FREE Full text] [CrossRef] [Medline]
    12. Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. Br Med J 2018 Dec 14;363:k4524 [FREE Full text] [CrossRef] [Medline]
    13. Moriarty F, Bennett K, Cahir C, Kenny RA, Fahey T. Potentially inappropriate prescribing according to STOPP and START and adverse outcomes in community-dwelling older people: a prospective cohort study. Br J Clin Pharmacol 2016 Dec;82(3):849-857 [FREE Full text] [CrossRef] [Medline]
    14. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc (2003) 2017;57(6):729-738.e10. [CrossRef] [Medline]
    15. Hill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther 2013 Oct;38(5):360-372. [CrossRef] [Medline]
    16. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992 Oct;45(10):1045-1051. [Medline]
    17. Motter FR, Fritzen JS, Hilmer SN, Paniz É, Paniz VM. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol 2018 Jun;74(6):679-700. [CrossRef] [Medline]
    18. Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. [Improving drug prescribing in the elderly: a new edition of STOPP/START criteria]. Rev Esp Geriatr Gerontol 2015;50(2):89-96. [CrossRef] [Medline]
    19. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015 Nov;63(11):2227-2246. [CrossRef] [Medline]
    20. Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther 2016 Apr;41(2):158-169. [CrossRef] [Medline]
    21. Reis W, Bonetti A, Bottacin W, Reis A, Souza T, Pontarolo R, et al. Impact on process results of clinical decision support systems (CDSSs) applied to medication use: overview of systematic reviews. Pharm Pract (Granada) 2017;15(4):1036 [FREE Full text] [CrossRef] [Medline]
    22. Clyne B, Bradley MC, Hughes C, Fahey T, Lapane KL. Electronic prescribing and other forms of technology to reduce inappropriate medication use and polypharmacy in older people: a review of current evidence. Clin Geriatr Med 2012 May;28(2):301-322. [CrossRef] [Medline]
    23. Soiza RL, Subbarayan S, Antonio C, Cruz-Jentoft AJ, Petrovic M, Gudmundsson A, et al. The SENATOR project: developing and trialling a novel software engine to optimize medications and nonpharmacological therapy in older people with multimorbidity and polypharmacy. Ther Adv Drug Saf 2017 Mar;8(3):81-85 [FREE Full text] [CrossRef] [Medline]
    24. Sönnichsen A, Trampisch US, Rieckert A, Piccoliori G, Vögele A, Flamm M, et al. Polypharmacy in chronic diseases-Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial. Trials 2016 Jan 29;17:57 [FREE Full text] [CrossRef] [Medline]
    25. Christiane M. U.S National Library of Medicine. 2018. Application for an Electronic Medication Management Support System (AdAM)   URL: https://clinicaltrials.gov/ct2/show/NCT03430336 [accessed 2020-01-13]
    26. Stefanie HM. U.S National Library of Medicine. OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People (OPERAM) Internet   URL: https://clinicaltrials.gov/ct2/show/NCT02986425
    27. Young A, Tordoff J, Dovey S, Reith D, Lloyd H, Tilyard M, et al. Using an electronic decision support tool to reduce inappropriate polypharmacy and optimize medicines: rationale and methods. JMIR Res Protoc 2016 Jun 10;5(2):e105 [FREE Full text] [CrossRef] [Medline]
    28. Barris Blundell D. Revisión de medicación según criterios STOPP/START en pacientes mayores del servicio de sistema personalizado de dosificación de medicamentos de una farmacia comunitaria. Farm Comunitarios 2015 Jun 01;7(2):31-36. [CrossRef]
    29. González-Rojano E, Acosta SV, Palacián DR, Hernández M, Abad-Santos F. Utility of Checkthemeds® for detection of potentially inappropriate medication in hospitalized patients. Clin Ther 2017 Aug;39(8):e37. [CrossRef]
    30. Prados-Torres A, Del Cura-González I, Prados-Torres D, López-Rodríguez JA, Leiva-Fernández F, Calderón-Larrañaga A, Multi-PAP Group. Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy: study protocol of a cluster randomized clinical trial (Multi-PAP project). Implement Sci 2017 Apr 27;12(1):54 [FREE Full text] [CrossRef] [Medline]
    31. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C, del Grupo de Determinantes Sociales de Sociedad Española de Epidemiología. [Proposals for social class classification based on the Spanish National Classification of Occupations 2011 using neo-Weberian and neo-Marxist approaches]. Gac Sanit 2013;27(3):263-272 [FREE Full text] [CrossRef] [Medline]
    32. O'Halloran J, Miller G, Britt H. Defining chronic conditions for primary care with ICPC-2. Fam Pract 2004 Aug;21(4):381-386. [CrossRef] [Medline]
    33. O Riordan D, Aubert CE, Walsh KA, Van Dorland A, Rodondi N, Du Puy RS, et al. Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study. BMJ Open 2018 Mar 22;8(3):e019003 [FREE Full text] [CrossRef] [Medline]
    34. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol 2015 Dec;71(12):1415-1427. [CrossRef] [Medline]
    35. Zhang X, Zhou S, Pan K, Li X, Zhao X, Zhou Y, et al. Potentially inappropriate medications in hospitalized older patients: a cross-sectional study using the Beers 2015 criteria versus the 2012 criteria. Clin Interv Aging 2017;12:1697-1703 [FREE Full text] [CrossRef] [Medline]
    36. Kim GJ, Lee KH, Kim JH. South Korean geriatrics on Beers Criteria medications at risk of adverse drug events. PLoS One 2018;13(3):e0191376 [FREE Full text] [CrossRef] [Medline]
    37. Blanco-Reina E, Ariza-Zafra G, Ocaña-Riola R, León-Ortiz M. 2012 American Geriatrics Society Beers criteria: enhanced applicability for detecting potentially inappropriate medications in European older adults? A comparison with the Screening Tool of Older Person's Potentially Inappropriate Prescriptions. J Am Geriatr Soc 2014 Jul;62(7):1217-1223. [CrossRef] [Medline]
    38. Lucchetti G, Lucchetti AL. Inappropriate prescribing in older persons: a systematic review of medications available in different criteria. Arch Gerontol Geriatr 2017;68:55-61. [CrossRef] [Medline]
    39. Pastor Cano J, Aranda García A, Gascón Cánovas JJ, Rausell Rausell VJ, Tobaruela Soto M. [Beers versus STOPP criteria and the possible implications of the Beers criteria's Spanish adaptation]. Farm Hosp 2017 Jan 01;41(n01):130-131 [FREE Full text] [CrossRef] [Medline]
    40. Meulendijk MC, Spruit MR, Drenth-van MA, Numans ME, Brinkkemper S, Jansen PA, et al. Computerized decision support improves medication review effectiveness: an experiment evaluating the STRIP assistant's usability. Drugs Aging 2015 Jun;32(6):495-503 [FREE Full text] [CrossRef] [Medline]
    41. Niehoff KM, Rajeevan N, Charpentier PA, Miller PL, Goldstein MK, Fried TR. Development of the tool to reduce inappropriate medications (TRIM): a clinical decision support system to improve medication prescribing for older adults. Pharmacotherapy 2016 May 28;36(6):694-701. [CrossRef]
    42. Nauta KJ, Groenhof F, Schuling J, Hugtenburg JG, van Hout HP, Haaijer-Ruskamp FM, et al. Application of the STOPP/START criteria to a medical record database. Pharmacoepidemiol Drug Saf 2017 Oct;26(10):1242-1247. [CrossRef] [Medline]
    43. Anrys P, Boland B, Degryse J, De Lepeleire J, Petrovic M, Marien S, et al. STOPP/START version 2-development of software applications: easier said than done? Age Ageing 2016 Sep;45(5):589-592. [CrossRef] [Medline]
    44. Price M, Davies I, Rusk R, Lesperance M, Weber J. Applying STOPP guidelines in primary care through electronic medical record decision support: randomized control trial highlighting the importance of data quality. JMIR Med Inform 2017 Jun 15;5(2):e15 [FREE Full text] [CrossRef] [Medline]


    Abbreviations

    ATC: Anatomical Therapeutic Chemical
    ATC-N: Anatomical Therapeutic Chemical classification system-nervous system
    BZD: benzodiazepines
    COPD: chronic obstructive pulmonary disease
    DCN: data collection notebook
    ECDSS: electronic clinical decision support system
    Multi-PAP: Multimorbidity and Polypharmacy in Primary Care
    NSAID: nonsteroidal anti-inflammatory drug
    OR: odds ratio
    PIP: potentially inappropriate prescribing
    PPI: proton pump inhibitor
    START: Screening Tool to Alert doctors to Right Treatment
    STOPP: Screening Tool of Older Person’s Prescription
    V2: version 2


    Edited by G Eysenbach; submitted 25.03.19; peer-reviewed by A Smith, J Varghese; comments to author 17.10.19; revised version received 22.10.19; accepted 17.12.19; published 03.03.20

    ©Eloisa A Rogero-Blanco, Juan A Lopez-Rodriguez, Teresa Sanz-Cuesta, Mercedes Aza-Pascual-Salcedo, M Jose Bujalance-Zafra, Isabel Cura-Gonzalez, MultiPAP Group. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 03.03.2020.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Medical Informatics, is properly cited. The complete bibliographic information, a link to the original publication on http://medinform.jmir.org/, as well as this copyright and license information must be included.